410 related articles for article (PubMed ID: 32265927)
1. Escape or Fight: Inhibitors in Hemophilia A.
Merlin S; Follenzi A
Front Immunol; 2020; 11():476. PubMed ID: 32265927
[TBL] [Abstract][Full Text] [Related]
2. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
3. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
Kitazawa T; Shima M
Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
[TBL] [Abstract][Full Text] [Related]
4. Review of immune tolerance induction in hemophilia A.
Schep SJ; Schutgens REG; Fischer K; Boes ML
Blood Rev; 2018 Jul; 32(4):326-338. PubMed ID: 29482894
[TBL] [Abstract][Full Text] [Related]
5. Tolerating Factor VIII: Recent Progress.
Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
Front Immunol; 2019; 10():2991. PubMed ID: 31998296
[TBL] [Abstract][Full Text] [Related]
6. Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
Groomes CL; Gianferante DM; Crouch GD; Parekh DS; Scott DW; Lieuw K
Pediatr Blood Cancer; 2016 May; 63(5):922-4. PubMed ID: 26739399
[TBL] [Abstract][Full Text] [Related]
7. Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.
Ragni MV; Malec LM
Expert Rev Hematol; 2014 Dec; 7(6):747-55. PubMed ID: 25374055
[TBL] [Abstract][Full Text] [Related]
8. Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.
Becker-Gotot J; Meissner M; Kotov V; Jurado-Mestre B; Maione A; Pannek A; Albert T; Flores C; Schildberg FA; Gleeson PA; Reipert BM; Oldenburg J; Kurts C
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36107620
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibody mimicking factor VIII.
Nogami K
Thromb Res; 2016 May; 141 Suppl 2():S34-5. PubMed ID: 27207420
[TBL] [Abstract][Full Text] [Related]
10. Innovating immune tolerance induction for haemophilia.
Batsuli G; Meeks SL; Herzog RW; Lacroix-Desmazes S
Haemophilia; 2016 Jul; 22 Suppl 5():31-5. PubMed ID: 27405673
[TBL] [Abstract][Full Text] [Related]
11. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
Kitazawa T; Igawa T; Sampei Z; Muto A; Kojima T; Soeda T; Yoshihashi K; Okuyama-Nishida Y; Saito H; Tsunoda H; Suzuki T; Adachi H; Miyazaki T; Ishii S; Kamata-Sakurai M; Iida T; Harada A; Esaki K; Funaki M; Moriyama C; Tanaka E; Kikuchi Y; Wakabayashi T; Wada M; Goto M; Toyoda T; Ueyama A; Suzuki S; Haraya K; Tachibana T; Kawabe Y; Shima M; Yoshioka A; Hattori K
Nat Med; 2012 Oct; 18(10):1570-4. PubMed ID: 23023498
[TBL] [Abstract][Full Text] [Related]
12. [Immune mechanisms involved in the development and eradication of anti-factor VIII alloantibodies in hemophilia].
Ishiguro A
Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(6):476-84. PubMed ID: 22214808
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW
Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors: A Need for Eradication?
Santagostino E; Young G; Escuriola Ettingshausen C; Jimenez-Yuste V; Carcao M
Acta Haematol; 2019; 141(3):151-155. PubMed ID: 30783066
[TBL] [Abstract][Full Text] [Related]
15. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
[TBL] [Abstract][Full Text] [Related]
16. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.
Matino D; Gargaro M; Santagostino E; Di Minno MN; Castaman G; Morfini M; Rocino A; Mancuso ME; Di Minno G; Coppola A; Talesa VN; Volpi C; Vacca C; Orabona C; Iannitti R; Mazzucconi MG; Santoro C; Tosti A; Chiappalupi S; Sorci G; Tagariello G; Belvini D; Radossi P; Landolfi R; Fuchs D; Boon L; Pirro M; Marchesini E; Grohmann U; Puccetti P; Iorio A; Fallarino F
J Clin Invest; 2015 Oct; 125(10):3766-81. PubMed ID: 26426076
[TBL] [Abstract][Full Text] [Related]
17. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?
Valentino LA; Ozelo MC; Herzog RW; Key NS; Pishko AM; Ragni MV; Samelson-Jones BJ; Lillicrap D
J Thromb Haemost; 2023 Nov; 21(11):3033-3044. PubMed ID: 37225021
[TBL] [Abstract][Full Text] [Related]
18. Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time.
Nakar C; Shapiro A
Transfus Apher Sci; 2019 Oct; 58(5):578-589. PubMed ID: 31447396
[TBL] [Abstract][Full Text] [Related]
19. CD4
Fu RY; Chen AC; Lyle MJ; Chen CY; Liu CL; Miao CH
Cell Immunol; 2020 Dec; 358():104216. PubMed ID: 32987195
[TBL] [Abstract][Full Text] [Related]
20. Induction of tolerance to factor VIII by transient co-administration with rapamycin.
Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW
J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
